The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot
May 08
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 09, 2025
DataAggregated Company Financials
Companies567
- 7D-6.1%
- 3M-11.2%
- 1Y-13.2%
- YTD-8.1%
Over the last 7 days, the Biotech industry has dropped 7.7%, driven by Vertex Pharmaceuticals declining 14%. On the other hand Natera is actually up 7.4%. Overall the industry is down 14% in 12 months. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 09 May 2025 | US$890.8b | US$155.2b | -US$25,508,884,067.76 | 18.2x | -34.9x | 5.7x |
| Sun, 06 Apr 2025 | US$735.9b | US$118.6b | -US$37,018,260,571.73 | 20.1x | -19.9x | 6.2x |
| Tue, 04 Mar 2025 | US$851.9b | US$119.0b | -US$37,239,165,117.46 | 18.7x | -22.9x | 7.2x |
| Thu, 30 Jan 2025 | US$991.6b | US$149.5b | -US$26,328,617,325.65 | 17.4x | -37.7x | 6.6x |
| Sat, 28 Dec 2024 | US$987.9b | US$149.9b | -US$26,371,086,316.30 | 16.2x | -37.5x | 6.6x |
| Mon, 25 Nov 2024 | US$1.0t | US$150.0b | -US$26,558,578,256.44 | 16.6x | -38.3x | 6.8x |
| Wed, 23 Oct 2024 | US$895.9b | US$113.1b | -US$36,020,987,135.80 | 21.4x | -24.9x | 7.9x |
| Fri, 20 Sep 2024 | US$919.7b | US$113.2b | -US$35,956,842,944.72 | 22.1x | -25.6x | 8.1x |
| Sun, 18 Aug 2024 | US$883.1b | US$113.2b | -US$35,819,260,655.83 | 22.3x | -24.7x | 7.8x |
| Tue, 16 Jul 2024 | US$1.2t | US$164.5b | -US$28,103,794,830.82 | 29x | -42.5x | 7.3x |
| Thu, 13 Jun 2024 | US$1.2t | US$164.5b | -US$28,092,824,135.28 | 28x | -41.1x | 7x |
| Sat, 11 May 2024 | US$1.1t | US$164.6b | -US$26,942,623,519.83 | 23.3x | -41.5x | 6.8x |
| Mon, 08 Apr 2024 | US$1.1t | US$164.4b | -US$23,377,298,863.03 | 21.3x | -48.3x | 6.9x |
| Wed, 06 Mar 2024 | US$1.2t | US$167.9b | -US$21,336,854,000.78 | 16.1x | -55.9x | 7.1x |
| Fri, 02 Feb 2024 | US$1.4t | US$204.7b | -US$22,768,331,138.00 | 19x | -63.6x | 7.1x |
| Sun, 31 Dec 2023 | US$1.4t | US$204.9b | -US$22,199,644,413.00 | 19.8x | -62.6x | 6.8x |
| Tue, 28 Nov 2023 | US$1.2t | US$204.8b | -US$22,010,873,467.00 | 18.7x | -55.7x | 6x |
| Thu, 26 Oct 2023 | US$1.2t | US$207.4b | -US$13,064,474,784.00 | 16.4x | -92.7x | 5.8x |
| Sat, 23 Sep 2023 | US$1.3t | US$207.5b | -US$12,879,348,159.00 | 17.1x | -97.9x | 6.1x |
| Mon, 21 Aug 2023 | US$1.3t | US$207.6b | -US$12,372,676,716.00 | 17.6x | -102.2x | 6.1x |
| Wed, 19 Jul 2023 | US$1.1t | US$186.7b | -US$15,964,743,132.00 | 12.8x | -71.3x | 6.1x |
| Fri, 16 Jun 2023 | US$1.2t | US$186.3b | -US$15,880,859,492.00 | 12.2x | -72.5x | 6.2x |
| Sun, 14 May 2023 | US$1.2t | US$191.7b | -US$12,222,188,637.00 | 13.8x | -94.4x | 6x |
| Tue, 11 Apr 2023 | US$1.2t | US$198.2b | -US$3,345,249,969.00 | 13.8x | -346.3x | 5.8x |
| Thu, 09 Mar 2023 | US$1.1t | US$199.1b | -US$4,824,949,147.00 | 15x | -232.6x | 5.6x |
| Sat, 04 Feb 2023 | US$1.2t | US$203.6b | US$1.7b | 15.6x | 703.6x | 5.7x |
| Mon, 02 Jan 2023 | US$1.2t | US$203.5b | US$1.7b | 14.3x | 667.5x | 5.7x |
| Wed, 30 Nov 2022 | US$1.1t | US$202.2b | US$1.3b | 14.6x | 876.7x | 5.5x |
| Fri, 28 Oct 2022 | US$1.1t | US$205.5b | US$7.3b | 14x | 147.6x | 5.3x |
| Sun, 25 Sep 2022 | US$1.0t | US$206.0b | US$5.6b | 13.9x | 182.3x | 4.9x |
| Tue, 23 Aug 2022 | US$1.1t | US$206.2b | US$7.2b | 15.6x | 147.4x | 5.2x |
| Thu, 21 Jul 2022 | US$1.1t | US$211.6b | US$10.7b | 17.1x | 101.1x | 5.1x |
| Sat, 18 Jun 2022 | US$922.9b | US$212.2b | US$10.9b | 14.8x | 84.4x | 4.3x |
| Mon, 16 May 2022 | US$993.9b | US$212.0b | US$10.6b | 15.6x | 94.1x | 4.7x |
Price to Earnings Ratio
94.1x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.33% | |
| Healthcare | -1.67% | |
| Biotech | -6.14% | |
| Biotech | -6.14% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NTRA Natera | US$162.57 | 7.4% +US$1.5b | 70.1% | PS13x | |
| EXAS Exact Sciences | US$53.06 | 12.5% +US$1.1b | -2.0% | PS3.5x | |
| NBIX Neurocrine Biosciences | US$117.52 | 10.3% +US$1.1b | -15.9% | PE38x | |
| HALO Halozyme Therapeutics | US$67.73 | 12.8% +US$930.1m | 54.5% | PE17.2x | |
| UTHR United Therapeutics | US$308.00 | 4.8% +US$638.3m | 15.8% | PE11.5x |